Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

inhibiTOR

Financiado

Novel selective mTORC1 inhibitors

Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and the fourth leading cause of cancer-related deaths worldwide. The multikinase inhibitor sorafenib is the only approved drug to treat HCC and on average enha... ver más

31/12/2021

UNIVERSITAT BASEL

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITAT BASEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 5 años

0% 100%

2 Participantes

UNIVERSITAT BASEL

150.00K€ | Lider

MULTISCAN TECHNOLOGIES

241.74K€ | Participante

Proyectos interesantes

PDC2021-121119-I00 PEPTIDOMIMETICOS INHIBIDORES DE KRAS COMO TERAPIA DIRIGIDA P... 148K€ Cerrado

PDC2021-121147-I00 TRATAMIENTO DEL CARCINOMA HEPATOCELULAR CON NUEVOS INHIBIDOR... 150K€ Cerrado

PID2020-119164RB-I00 GENERACION DE UN MODELO KNOCKOUT DE LOS FACTORES INDUCIBLES... 85K€ Cerrado

BES-2017-081286 MECANISMOS DE RESISTENCIA ADQUIRIDA A SORAFENIB EN EL CARCIN... 93K€ Cerrado

BFU2012-38867 MTOR, DIANA TERAPEUTICA PARA HCC: PAPEL DE E2F1 Y LA RESISTE... 138K€ Cerrado

SAF2015-64237-R DESARROLLO DE NUEVAS HERRAMIENTAS FARMACOLOGICAS ANTITUMORAL... 121K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 24 meses Fecha Inicio: 2019-12-19
Fecha Fin: 2021-12-31

Líder del proyecto

UNIVERSITAT BASEL

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and the fourth leading cause of cancer-related deaths worldwide. The multikinase inhibitor sorafenib is the only approved drug to treat HCC and on average enhances survival by three months. Thus, the efficacy of current HCC treatment options is very limited. Studies in the context of our ERC-Synergy grant revealed that sorafenib resistance correlates with upregulation of mammalian target of rapamycin complex 1 (mTORC1) signaling. The central role of mTORC1 in conferring therapy resistance suggests that effective therapy against HCC may require combination of a primary inhibitor (e.g., sorafenib) and an mTORC1 inhibitor. The mTORC1 inhibitor rapamycin and its derivatives (rapalogs) are approved for a few advanced cancers, but not for HCC. Their clinical applicability is limited by their effectiveness and safety. Rapalogs fail to completely inhibit mTORC1 as they have little effect on inhibiting phosphorylation of 4E-BP, one of the two main targets of mTORC1. Moreover, rapamycin and rapalogs also inhibit mTORC2 when chronically administered, leading to undesirable effects such as hyperglycemia, hyperlipidemia, and insulin resistance. We have established a biophysical assay to identify selective mTORC1 inhibitors with a novel, rapalog-unrelated, mechanism of action. We predict these inhibitors to be more selective, more effective, and potentially safer than mTORC1 inhibitors currently used in the clinic. In this Proof of Concept project, we aim to study the pharmacological potential of selective and efficient mTORC1 inhibition alone or in combination therapy with sorafenib to treat HCC.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores